Metabolex, Inc.’s MBX-102/JNJ-39659100 (metaglidasen) Reduced Inflammation in Preclinical Diabetes Models
Both mice and rats treated with either active compound demonstrated substantially reduced inflammation and macrophage infiltration in adipose tissue. In addition, treatment with MBX102/JNJ39659100 suppressed the expression of key inflammatory genes in adipose tissue and macrophages.- In addition to its role in reducing inflammation, a 217-patient Phase 2 study showed that MBX-102/JNJ-39659100 has a positive effect on glucose and lipid levels and was well-tolerated.
In a strategic alliance with Ortho-McNeil, Inc. in June 2006, Ortho-McNeil has been entitled to an exclusive license for worldwide development and commercialization of MBX-102/JNJ-39659100.
Metabolex (205073) is now testing MBX-102/JNJ-39659100 in a 400-patient Phase 2/3 clinical trial.
Find more details from the press release.
.jpg)
Comment Preview